BCL2L2-PABPN1 is a read-through fusion transcript arising from cis-splicing between adjacent genes BCL2L2 and PABPN1 on chromosome 14, generated through RNA processing rather than genomic rearrangement 1. The fusion protein contains functional domains from both parents (BH4, BCL, and RRM domains) and is conserved across multiple species including humans, rats, and pigs 12. Primary functions vary by tissue context. In glioblastoma cells, BCL2L2-PABPN1 promotes tumor progression by blocking Bax activity and activating the PI3K/AKT pathway, with knockdown suppressing cell proliferation, migration, and invasion 1. In porcine adipose tissue, it promotes preadipocyte proliferation while inhibiting differentiation, operating through MAPK and PI3K-Akt pathways and miR-339-3p regulation 2. Clinical significance includes elevated expression in bladder urothelial carcinoma compared to adjacent normal tissue, suggesting potential diagnostic or biomarker utility 3. Additionally, BCL2L2-PABPN1 is associated with metabolic phenotypes including basal metabolic rate, obesity-related metabolites, and methylation alterations in mild cognitive impairment, implicating roles in metabolic dysfunction and neuroinflammation 45. The fusion transcript localizes primarily to the cell nucleus, suggesting possible long non-coding RNA function 3.